• Something wrong with this record ?

Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study

L. Karnisova, O. Hradsky, K. Blahova, F. Fencl, Z. Dolezel, T. Zaoral, J. Zieg,

. 2018 ; 177 (12) : 1837-1844. [pub] 20180924

Language English Country Germany

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 1996-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost) from 2012-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 1997-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 1996-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1996-01-01 to 1 year ago
Family Health Database (ProQuest) from 1996-01-01 to 1 year ago
Public Health Database (ProQuest) from 1996-01-01 to 1 year ago

Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r = - 0.62, p = 0.0001) and the initial glomerular filtration rate (r = 0.36, p = 0.026). Patients with C3 < 0.825 g/L needed renal replacement therapy and also had significantly more renal complications (p = 0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome. What is Known: • Shiga toxin modulates the function of complement regulatory proteins and thus contributes to complement activation in patients with diarrhea-associated hemolytic uremic syndrome. • Risk factors that can predict the need for acute renal replacement therapy and poor outcome in patients with diarrhea-associated hemolytic uremic syndrome are mainly the combination of oligoanuria, dehydration, leukocytosis, high hematocrit > 23%, and neurological involvement. What is New: • A lowered concentration of C3 at the time of initial presentation of diarrhea-associated hemolytic uremic syndrome was associated with more severe renal failure and the need for renal replacement therapy along with the development of more extra renal complications. • Decreased C3 at admission can predict complicated course of diarrhea-associated hemolytic uremic syndrome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000352
003      
CZ-PrNML
005      
20190118112819.0
007      
ta
008      
190107s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00431-018-3255-2 $2 doi
035    __
$a (PubMed)30251107
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Karnisova, Lucia $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic. Lucia.Karnisova@fnmotol.cz.
245    10
$a Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study / $c L. Karnisova, O. Hradsky, K. Blahova, F. Fencl, Z. Dolezel, T. Zaoral, J. Zieg,
520    9_
$a Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r = - 0.62, p = 0.0001) and the initial glomerular filtration rate (r = 0.36, p = 0.026). Patients with C3 < 0.825 g/L needed renal replacement therapy and also had significantly more renal complications (p = 0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome. What is Known: • Shiga toxin modulates the function of complement regulatory proteins and thus contributes to complement activation in patients with diarrhea-associated hemolytic uremic syndrome. • Risk factors that can predict the need for acute renal replacement therapy and poor outcome in patients with diarrhea-associated hemolytic uremic syndrome are mainly the combination of oligoanuria, dehydration, leukocytosis, high hematocrit > 23%, and neurological involvement. What is New: • A lowered concentration of C3 at the time of initial presentation of diarrhea-associated hemolytic uremic syndrome was associated with more severe renal failure and the need for renal replacement therapy along with the development of more extra renal complications. • Decreased C3 at admission can predict complicated course of diarrhea-associated hemolytic uremic syndrome.
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a aktivace komplementu $x imunologie $7 D003167
650    _2
$a komplement C3 $x analýza $7 D003176
650    _2
$a Česká republika $7 D018153
650    _2
$a průjem $x komplikace $x imunologie $7 D003967
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hemolyticko-uremický syndrom $x komplikace $x imunologie $7 D006463
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a ledviny $x patofyziologie $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prognóza $7 D011379
650    _2
$a ROC křivka $7 D012372
650    _2
$a dialýza ledvin $x statistika a číselné údaje $7 D006435
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hradsky, Ondrej $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Blahova, Kveta $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Fencl, Filip $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Dolezel, Zdenek $u Paediatric Clinic, University Hospital Brno, Medical Faculty of Masaryk University, Brno, Czech Republic.
700    1_
$a Zaoral, Tomas $u The Clinic of Paediatrics, Faculty of Medicine, University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Zieg, Jakub $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00009638 $t European journal of pediatrics $x 1432-1076 $g Roč. 177, č. 12 (2018), s. 1837-1844
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30251107 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118113033 $b ABA008
999    __
$a ok $b bmc $g 1364459 $s 1038475
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 177 $c 12 $d 1837-1844 $e 20180924 $i 1432-1076 $m European journal of pediatrics $n Eur J Pediatr $x MED00009638
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...